[Bisphosphonate-induced osteonecrosis of the jaws--a guide to diagnosis, therapy and prevention of BON in dental practice].
Since four years from now on more and more information about bisphosphonate induced osteonecrosis of the jaws is published not only in professional journals, but also in the mass media. The result is a growing uncertainty of patients, but also professionals in dealing with this group of medication. Usually bisphosphonates are prescribed for treatment of severe osteoporosis, but also for treatment of metastatic bone disease and tumor induced hypercalcemia. The following article gives information about bisphosphonates, bisphosphonate induced osteonecrosis of the jaws (BON) and potential risk factors. Additionally it shows the typical clinical picture, necessary diagnostic measures and informs about possible prevention strategies especially for dentists in daily practice.
Dannemann
Christine
C
Klinik und Poliklinik für Kiefer- und Gesichtschirurgie, UniversitätsSpitaL Zürich. christine.dannemann@usz.ch
Grätz
Klaus W
KW
Zwahlen
Roger A
RA
D000890:Anti-Infective Agents / Q000627:therapeutic use; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D004164:Diphosphonates / Q000009:adverse effects*; D017408:Guidelines as Topic; D006801:Humans; D007571:Jaw Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy; D019647:Oral Surgical Procedures / Q000009:adverse effects; D010020:Osteonecrosis / Q000139:chemically induced* / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy; D012307:Risk Factors
D000890:Anti-Infective Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates